entertainment -WSS

entertainment

author：comprehensive 2025-09-30 00:36:44 - browse：5381

Drugmakers already bet big on mRNA for cancer. Now President Biden is going in, too? Anna Moneymaker/Getty Images

WASHINGTON — President Biden’s fledgling health agency, designed to accelerate under-funded research, just set its sights on one of the hottest areas of medicine — and one where the drug industry has a multibillion-dollar head start.

The White House announced Wednesday that the Advanced Research Projects Agency for Health would bankroll a $24 million project by Emory University to build messenger RNA platforms to target “cancer and other diseases,” investing in the technology behind the U.S.’s most commonly used vaccines for Covid-19.

The administration touted the news of CUREIT as the latest in Biden’s longtime mission to rein in cancer deaths, the Cancer Moonshot. But by using mRNA to treat cancer, ARPA-H is wading into a field that has advanced in fits and starts — and whose industry leaders have already spent multiples of the program’s entire budget into their own research. Moderna and BioNTech, massively profitable companies that have sold more than $80 billion worth of Covid-19 vaccines combined, have singled out oncology as the next big application for mRNA and invested accordingly.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Akili, maker of video game for ADHD, to be acquired for 34 million

hotspot

WSS

MultiPlan and major insurers sued for alleged medical price

Biohaven protein

Focused ultrasound for uterine fibroids: an uphill battle

Report: NIH

Health care needs a new profession: neuroimaging counseling

Q&A: Jennifer Adair on making gene therapy available globally

knowledge

entertainment

Wikipedia

Continuity nursing helped my family in our darkest PICU moments

H5N1 bird flu found in pasteurized milk: what we know

Medical leaders decry Supreme Court decision on affirmative action

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Alkermes shareholders re

Melinda French Gates resigns from Gates Foundation

Medical leaders decry Supreme Court decision on affirmative action

Bird flu in milk supply is likely coming from asymptomatic cows

Tori Bowie and the unacceptable rates of Black maternal death

Cell therapy fails to slow type 1 diabetes, but safety is established

leisure time

Lab trade group sues FDA to halt regulation of lab

Cancer researcher Catriona Jamieson is sending tumors into space

AI used to predict Covid

Cell therapy fails to slow type 1 diabetes, but safety is established

Health care needs a new profession: neuroimaging counseling

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

hotspot

knowledge

focus

hotspot